AstraZeneca (AZN LN) Q3 2026 (USD): Revenue 16.2bln (exp. 16bln), Adj. EPS 2.79 (exp. 2.59). Confirms FY26 guidance

• "We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars."
• "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.”

A revenue and adjusted EPS beat with guidance confirmed is the cleaner kind of large-cap pharma print: the shares in these setups have tended to trade on the guidance language and the pipeline framing rather than the quarter itself, since AstraZeneca's multiple rests more on the late-stage portfolio than on any single period. The emphasis on peak-year revenue potential across Phase III assets is a familiar CEO construction in this sector, and the historical read is that such aggregates are aspirational until readouts land, so the desk question is which specific programmes the figure depends on rather than the headline number. Confirmed guidance after a beat removes the classic disappointment risk of a raise-and-miss pattern later in the year, and past episodes of this kind have seen the initial move hold where the outlook language was left untouched. What follows from here is the usual sequence: the earnings call for margin detail and any commentary on pricing or tariff exposure, then the readout calendar, where positive Phase III results have historically been the events that actually re-rate the name. As a FTSE heavyweight, the print also feeds into the UK index and the European pharma peer set, where correlation on AstraZeneca results days has been the established pattern.